Back

Dipeptidyl peptidase 4 inhibitor sitagliptin ameliorates renal function in a model of hypertension-induced cardiorenal disease

28 May 2018 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Basic Science - Basic Science - Cardiac Diseases Cardiac Diseases HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Donato Cappetta

Second University of Naples, Naples (Italy)

28 More presentations in this session

Presentation thumbnail
Miss M. Lodi (Debrecen, HU)
Abstract
Presentation thumbnail
Doctor T. Kraft (Hannover, DE)
Abstract
Presentation thumbnail
Doctor J. Winkler (Vienna, AT)
Abstract
Presentation thumbnail
Associate Professor J. Holfeld (Salzburg, AT)
Abstract
Presentation thumbnail
Doctor A. Semenov (Turku, FI)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Basic Science - Basic Science - Cardiac Diseases

The Event

Event poster

Heart Failure 2018

28 May 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Meta-analysis of cardiovascular outcome trials assessing the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
27 August 2021
thumbnail
Congress Presentation
A soluble guanylate cyclase stimulator improves survival in a rat model of heart failure with reduced ejection fraction and chronic kidney disease induced by aorto-caval fistula and 5/6 nephrectomy
1 September 2025
thumbnail
Congress Presentation
Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction
1 September 2020
thumbnail
Webinar
GLP-1 RAs and HFpEF: which HFpEF patients should now be receiving GLP-1 RAs?
15 December 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources